We report the results of a prospective study of a reduced-intensity conditioning (RIC) regimen followed by allogeneic peripheral blood stem cell transplantation (PBSCT) from an HLA-identical sibling in 37 patients with acute myeloid leukemia (AML; n = 17) or myelodysplastic syndrome (MDS; n = 20). The median age was 57 years, and 22 (59%) were beyond the early phase of their disease. The incidence of grade II to IV acute graft-versus-host disease (GVHD) was 19% (5% grade III-IV), and the 1-year incidence of chronic extensive GVHD was 46%. With a median follow-up of 297 days (355 days in 24 survivors), the 1-year probability of transplant-related mortality was 5%, and the 1-year progression-free survival was 66%. The 1-year incidence of disease progression in patients with and without GVHD was 13% (95% CI, 4%-34%) and 58% (95% CI, 36%-96%), respectively (P = .008). These results suggest that a graft-versus-leukemia effect plays a crucial role in reducing the risk of relapse after a RIC allograft in AML and MDS.

Allogeneic hematopoietic stem cell transplantation (HSCT) with myeloablative conditioning is a valid treatment option for adults with high-risk myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML).1,2 Several groups of investigators have developed reduced-intensity conditioning (RIC) regimens, which led to engraftment of donor lymphoid and hematopoietic stem cells without the extrahematologic toxicities of traditional myeloablative transplants.3-10 However, experience with RIC HSCT in AML and MDS is limited. We herein report results of a prospective multicenter study of a RIC regimen followed by allogeneic peripheral blood stem cell transplantation (PBSCT), which is being conducted in several institutions in Spain.

Patient selection

Eligibility criteria for entry into this RIC allogeneic PBSCT program included patients with AML or high-risk MDS who were at least 50 years old or had undergone a prior autologous HSCT. Patients gave written informed consent for inclusion in the protocol, which was approved by all local ethical review boards and the Spanish Drug Agency (protocol 99-0151). Between December 1998 and September 2001, 37 patients underwent an RIC PBSCT from an HLA-identical sibling in 9 transplantation centers in Spain.

Patient characteristics are shown in Table1. Disease phase at transplantation was categorized as early in 15 cases (AML or MDS in first complete remission [CR] after chemotherapy and hypoplastic MDS) and nonearly in 22 cases.

Table 1.

Patient characteristics

CharacteristicNo.
No. of patients 37  
Age, median (range) 57  (22-66)  
Male sex (%) 20  (54)  
AML (%) 17  (46) 
 FAB subtype M0/M1/M2/M4/M5 2/5/7/1/2  
MDS (%) 20  (54)  
 Hypoplastic/RAEB 7/3 
 RAEB-t 7  
 CMML 3  
 IPSS score20  
  Intermediate-1 
  Intermediate-2 9  
  High 
 Intensive treatment for MDS prior to transplantation (%) 7  (35)  
 Time from diagnosis to transplantation, median mo (range) 5  (1-55)  
High-risk features at transplantation (%)  
 Poor-risk cytogenetics* 7  (19) 
 Secondary AML/MDS 1 (6)/5 (25) 
 Prior autologous transplantation 4  (11)  
 Blasts in BM ≥ 10% at transplantation 7  (19)  
 Nonearly disease phase at transplantation 22  (59)  
ECOG performance status ≥ 2 (%) 3  (8)  
Donor or recipient CMV seropositive (%) 36  (97)  
Sex mismatch (%) 14  (38) 
CD34+ cells infused (× 106/kg recipient weight), median (range) 5  (2-15) 
CharacteristicNo.
No. of patients 37  
Age, median (range) 57  (22-66)  
Male sex (%) 20  (54)  
AML (%) 17  (46) 
 FAB subtype M0/M1/M2/M4/M5 2/5/7/1/2  
MDS (%) 20  (54)  
 Hypoplastic/RAEB 7/3 
 RAEB-t 7  
 CMML 3  
 IPSS score20  
  Intermediate-1 
  Intermediate-2 9  
  High 
 Intensive treatment for MDS prior to transplantation (%) 7  (35)  
 Time from diagnosis to transplantation, median mo (range) 5  (1-55)  
High-risk features at transplantation (%)  
 Poor-risk cytogenetics* 7  (19) 
 Secondary AML/MDS 1 (6)/5 (25) 
 Prior autologous transplantation 4  (11)  
 Blasts in BM ≥ 10% at transplantation 7  (19)  
 Nonearly disease phase at transplantation 22  (59)  
ECOG performance status ≥ 2 (%) 3  (8)  
Donor or recipient CMV seropositive (%) 36  (97)  
Sex mismatch (%) 14  (38) 
CD34+ cells infused (× 106/kg recipient weight), median (range) 5  (2-15) 

FAB indicates French-American-British classification; RAEB, refractory anemia with excess blasts; RAEB-t, refractory anemia with excess blasts in transformation; CMML, chronic myelomonocytic leukemia; IPSS, International prognostic scoring system; ECOG, European Cooperative Oncology Group.

*

Includes cases with complex karyotypes, monosomy 7 and del(5); 9 patients had a normal karyotype and 19 had a cytogenetic abnormality not categorized as poor prognosis.

Includes 3 cases of secondary postautologous transplantation MDS, 2 cases of MDS secondary to chemotherapy and 1 case of AML secondary to chemotherapy.

Includes 8 cases (21%) of female donor to male recipient.

Conditioning regimen and supportive care

The RIC regimen consisted of fludarabine 30 mg /m2intravenously on days −9 to −5 and busulfan 1 mg/kg times 10 doses (days −6 to −4, total 10 mg/kg), as previously reported in detail.10 Graft-versus-host disease (GVHD) prophylaxis included cyclosporine A (CsA) plus short-course methotrexate (MTX), with CsA tapering starting on day +90 if no GVHD appeared. Infection prophylaxis, grading, and treatment of acute and chronic GVHD were done by standard methods.10 

Chimerism analysis

After transplantation, serial samples of unfractionated peripheral blood (PB) and bone marrow (BM) mononuclear cells were analyzed for degrees of donor-recipient chimerism using polymerase chain reaction (PCR) of informative minisatellite regions, as previously described in detail.10 

Statistical analysis

This interim analysis was done on March 15, 2002. The probability of progression-free survival (PFS) was estimated from the time of transplantation using Kaplan-Meier product-limit estimates. The probabilities of transplant-related mortality (TRM), disease progression, and acute and chronic GVHD were calculated using cumulative incidence estimates.11 Univariate Cox regression was used to analyze the association of various variables with disease progression, with GVHD included as a time-dependent covariate. A multivariate Cox regression analysis was done to confirm whether GVHD was an independent protective factor for disease progression, with inclusion of variables that showed a trend in univariate testing.

Early procedure-related toxicities were mild in all cases, and there were no early deaths.

Hematologic recovery and infections

Hematologic recovery was prompt in all cases. Neutrophils decreased to less than 0.5 × 109/L in all cases and recovered at a median of 16 days after transplantation (range, 11-27 days). The median times to reach a stable platelet count more than 20 × 109/L and more than 50 × 109/L were day +11 (range, days 0-36) and day +14 (range, days 11-51), respectively. Twenty patients (54%) developed uncomplicated febrile neutropenia. Thus far 7 patients have reactivated cytomegalovirus (CMV), which represents a 180-day probability of developing CMV infection of 20%.

Acute and chronic GVHD

Acute GVHD occurred in 14 patients (38%), which reached grade I in 7 cases, grade II in 5, and grade III in 2 cases. The 100-day incidence of grade II to IV acute GVHD was 19% (95% CI, 10%-37%). Twenty-one of 32 evaluable patients developed chronic GVHD, which was extensive in 11 cases, for a 1-year probability of chronic extensive GVHD of 43% (95% CI, 29%-65%).

Chimerism

On days +21 to +28, 24 (65%) patients were in complete donor chimerism (CDC) in PB and 21 of 28 (75%) in the BM, and on days +90 to +100 the rates of CDC were 25 of 31 (81%) and 17 of 20 (85%), respectively. On days +180 to +200 (n = 14) and beyond 1 year after transplantation (n = 10) all patients showed a pattern of CDC.

Responses and outcome

The median overall follow-up is 297 days (range, 61-1156 days). Currently 24 patients are alive, with a median follow-up of 355 days (range, 170-1156 days). Thirteen patients died, 10 from their underlying disease and 3 from TRM. The 1-year incidence of TRM is 5% (95% CI, 1%-21%), and the 1-year PFS is 66% (95% CI, 50%-81%). The 1-year incidence of disease progression is 28% (95% CI, 16%-47). In univariate analysis only the development of GVHD (defined as acute GVHD grade II-IV or chronic GVHD or both) conferred protection against disease progression, whereas disease phase (P = .1) and achieving CDC in PB within the first 100 days after transplantation (P = .15) showed a nonsignificant trend. The 1-year cumulative incidences of disease progression in patients with (n = 24) and without (n = 13) GVHD were 13% (95% CI, 4%-34%) and 58% (95% CI, 36%-96%), respectively (hazard rate [HR] for progression 6.3; 95% CI, 1.6-24.7; P = .008; Figure1). In multivariate Cox regression analysis including GVHD, achievement of CDC within 100 days (both as time-dependent covariates) and disease phase, only GVHD showed a protective effect on disease progression (HR for progression 7.5; 95% CI, 1.8-31.3; P = .006).

Fig. 1.

Disease progression after PBSCT.

Cumulative incidence of disease progression after allogeneic PBSCT with RIC in patients with (n = 24) and without (n = 13) GVHD (acute grade II-IV or chronic GVHD). The 1-year incidence of disease progression in patients with and without GVHD was 13% (95% CI, 4%-34%) and 58% (95% CI, 36%-96%), respectively (P = .008).

Fig. 1.

Disease progression after PBSCT.

Cumulative incidence of disease progression after allogeneic PBSCT with RIC in patients with (n = 24) and without (n = 13) GVHD (acute grade II-IV or chronic GVHD). The 1-year incidence of disease progression in patients with and without GVHD was 13% (95% CI, 4%-34%) and 58% (95% CI, 36%-96%), respectively (P = .008).

Close modal

Our results indicate that this fludarabine-busulfan RIC regimen is well tolerated and highly immunosuppressive, with no graft failures and a TRM of only 5%. TRM and disease progression are both high after an allogeneic HSCT in adult patients with AML and high-risk MDS.1,2,12 In these diseases the intensity of the conditioning regimens has been shown to have an influence on the risk of relapse, and thus RIC regimens may have a deleterious impact on PFS.13 On the other hand, several studies have shown that a graft-versus-leukemia effect may lead to a reduction of relapse in AML.14-16 

Few data are currently available regarding the results of RIC allografts in AML and MDS. Recently, the European Group for Blood and Marrow Transplantation Acute Leukemia Working Party described the results from a retrospective study that showed a 1-year TRM of 47% in 64 patients with AML and 48% in 53 patients with MDS; the relapse rates were 30% and 33%, respectively.17 A phase II study from Houston using fludarabine plus melphalan among 31 patients showed a 1-year TRM of 34% and an overall survival and PFS of 36% and 34%, respectively.4,18 Another study reported in abstract form described 47 patients with AML who underwent related (n = 26) or unrelated donor (n = 21) HSCT after a minimal conditioning regimen.19 After a median follow-up of 218 days, 12 related (46%) and 12 unrelated (60%) transplant recipients were alive in CR, with a TRM of 18%. These results agree with our prospective series of patients who received a homogeneous conditioning regimen and standard GVHD prophylaxis and supportive care. The most important observation in our study is that the risk of disease progression after transplantation was much lower in patients who developed acute or chronic GVHD than in those who did not. These differences cannot be easily explained by other relevant prognostic factors between the groups. As seen in Table 2, patients who developed GVHD had a trend for less early phases and had a longer follow-up, variables that intuitively should increase the risk of having a relapse. Additionally, in univariate and multivariate analysis, the only variable that decreased the HR of progressing was GVHD. This observation suggests that a graft-versus-leukemia effect does exist in AML and MDS after an RIC allograft. These results, however, should be interpreted with caution due to the small sample size, the relatively short follow-up, the few relapses observed, and the potential existence of undetected confounding factors.

Table 2.

Characteristics of patients with and without GVHD, defined as acute grade II-IV or chronic GVHD

Developed
GVHD
Did not develop
GVHD
No. of patients 24 13 
Median age (range) 57  (35-66) 58  (22-64)  
Male sex (%) 15  (62) 5  (38) 
AML/MDS 9/15 8/5  
Early disease phase* (%) 7  (29) 8  (61)  
Sex mismatch (%) 9  (37) 6  (46)  
100% donor chimerism in PB on d +30 (%) 15  (62) 9  (69)  
Achieved > 95% donor chimerism (%)
before d +100* 
18/20  (90) 7/11  (64)  
TRM (%) 2  (8) 1  (8)  
Follow-up, in d*(range) 330  (69-1156) 124  (61-489) 
Developed
GVHD
Did not develop
GVHD
No. of patients 24 13 
Median age (range) 57  (35-66) 58  (22-64)  
Male sex (%) 15  (62) 5  (38) 
AML/MDS 9/15 8/5  
Early disease phase* (%) 7  (29) 8  (61)  
Sex mismatch (%) 9  (37) 6  (46)  
100% donor chimerism in PB on d +30 (%) 15  (62) 9  (69)  
Achieved > 95% donor chimerism (%)
before d +100* 
18/20  (90) 7/11  (64)  
TRM (%) 2  (8) 1  (8)  
Follow-up, in d*(range) 330  (69-1156) 124  (61-489) 
*

All P values are > .2 except for early disease phase (P = .08), having achieved greater than 95% donor chimerism before day + 100 (P = .07) and follow-up (P = .04).

These results argue in favor of continuing the efforts to establish the role of RIC allografts in the long-term control of myeloid malignancies. However, for the meantime, young patients with AML or MDS should receive standard myeloablative conditioning prior to undergoing an allogeneic HSCT, whereas patients at high risk for TRM may be offered an RIC allograft within a clinical trial.

Prepublished online as

Blood First Edition Paper, April 30, 2002; DOI 10.1182/blood-2002-02-0400.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 U.S.C. section 1734.

1
De Witte
T
Hermans
J
Vossen
J
et al
Haematopoietic stem cell transplantation for patients with myelodysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf on the chronic leukaemia working party of the European Group for Blood and Marrow Transplantation.
Br J Haematol.
110
2000
620
630
2
Sierra J, Pérez WS, Rozman C, et al. Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood. In press.
3
Giralt
S
Estey
E
Albitar
M
et al
Engraftment of allogeneic haematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy.
Blood.
89
1997
4531
4536
4
Giralt
S
Thall
PF
Khouri
I
et al
Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation.
Blood.
97
2001
631
637
5
Slavin
S
Nagler
A
Naparstek
E
et al
Non-myeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant haematologic diseases.
Blood.
91
1998
756
763
6
Khouri
IF
Keating
M
Przepiorka
D
et al
Transplant lite: induction of graft-versus-malignancy using fludarabine-based non-ablative chemotherapy and allogeneic blood progenitor cell transplantation as treatment for lymphoid malignancy.
J Clin Oncol.
8
1998
2817
2824
7
McSweeney
PA
Niederwieser
D
Shizuru
JA
et al
Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects.
Blood.
97
2001
3390
3400
8
Kottaridis
PD
Milligan
DW
Chopra
R
et al
In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation.
Blood.
96
2000
2419
2425
9
Carella
AM
Giralt
S
Slavin
S
Nonmyeloablative therapy with allogeneic hematopoietic stem cell transplantation as treatment of hematological neoplasia.
Haematologica.
85
2000
304
313
10
Martino
R
Caballero
MD
Canals
C
et al
Allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: results of a prospective multicenter study.
Br J Haematol.
115
2001
653
659
11
Gooley
TA
Leisenring
W
Crowley
J
Storer
BE
Estimation of failure probabilities in the presence of competing risks: new representations of old estimations.
Stat Med.
18
1999
695
706
12
Anonymous
Report on the state of the art in blood and marrow transplantation—the IBMTR/ABMTR summary slides with guide.
IBMTR/ ABMTR Newsletter.
7
2000
3
10
13
Bacigalupo
A
Vitale
V
Corvò
R
et al
The combined effect of total body irradiation and cyclosporin A on the risk of relapse in patients with acute myeloid leukaemia undergoing allogeneic bone marrow transplantation.
Br J Haematol.
108
2000
99
104
14
Horowitz
MM
Gale
RP
Sondel
PM
et al
Graft-versus-leukemia reactions after bone marrow transplantation.
Blood.
75
1990
555
562
15
Weiden
PL
Sullivan
KM
Flournoy
N
Storb
R
Thomas
ED
Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation.
N Engl J Med.
304
1981
1529
1533
16
Bacigalupo
A
van Lint
MT
Occhini
D
et al
Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia.
Blood.
77
1991
1423
1428
17
Rezvani
K
Lalancette
M
Szydlo
R
et al
Non-myeloablative stem cell transplant in AML, ALL and MDS: disappointing outcome for patients with advanced disease [abstract].
Blood.
96
2000
2061a
18
Giralt
S
Update on clinical experience with NST: The M. D. Anderson Cancer Center experience in myeloid leukemia.
IBMTR/ABMTR Newsletter.
8
2001
5
6
19
Hegenbart
U
Sandmaier
P
Lange
T
et al
Graft versus leukemia effect after related and unrelated allogeneic hematopoietic stem cell transplants (HSCT) in patients with acute myeloid leukemia (AML) following minimal conditioning [abstract].
Blood.
98
2001
2814a
20
Greenberg
P
Cox
C
LeBeau
MM
et al
International scoring system for evaluating prognosis in myelodysplastic syndromes.
Blood.
89
1997
2079
2088

Author notes

Rodrigo Martino, Servei d'Hematologia Clı́nica, Hospital de la Santa Creu i Sant Pau, Av Sant Antoni Ma. Claret, 167 08025 Barcelona, Spain; e-mail:rmartino@hsp.santpau.es.

Sign in via your Institution